Natera shares are trading higher after the company announced a new study published in Molecular Oncology comparing the performance of mean tumor molecules per milliliter against mean variant allele frequency for measuring circulating tumor DNA using Signatera.
Portfolio Pulse from Benzinga Newsdesk
Natera's stock is up following the announcement of a new study published in Molecular Oncology. The study compares the performance of two metrics for measuring circulating tumor DNA using Natera's Signatera test: mean tumor molecules per milliliter and mean variant allele frequency.
December 21, 2023 | 5:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Natera's announcement of a new study highlighting the effectiveness of its Signatera test has led to an increase in its stock price.
The positive news about the published study is likely to boost investor confidence in Natera's Signatera test, potentially leading to increased adoption and sales. This optimism is reflected in the stock's price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100